Pharmaceutical pollution 'invisibly' poisoning Bangladesh's rivers, warns report
Synopsis
Bangladesh's rivers are being silently poisoned by pharmaceutical residues — antibiotics, hormones, and chemical intermediates — that are invisible to the eye yet biologically active for years. With fishing communities already vulnerable and antimicrobial resistance identified as the most dangerous downstream risk, a new report calls for urgent corporate and regulatory accountability across the country's fast-growing pharma sector.
Key Takeaways
Antibiotics, hormones, and other active pharmaceutical ingredients are invisibly polluting rivers across Bangladesh , according to a report in Prothom Alo .
A 2026 study of Gazipur water sources detected pharmaceutical compounds and heavy metals in hospital wastewater, industrial effluents, and river water.
Environmental scientist Prof.
Dr Shahriar Hossain identified pharmaceutical manufacturing and discarded household medicines as the two primary pollution sources.
Antimicrobial resistance (AMR) is described as the 'most dangerous dimension' of pharmaceutical pollution, as antibiotic residues favour the growth of resistant organisms.
Fishing communities in Bangladesh are called 'particularly vulnerable,' with both health and livelihoods at risk from ongoing water contamination.
The report urges investment in cleaner production, advanced wastewater treatment, and transparent environmental reporting across Bangladesh's pharma sector.
Antibiotics, hormones, anti-inflammatory drugs, and other active pharmaceutical ingredients (APIs) are silently contaminating rivers across Bangladesh, threatening aquatic ecosystems and the livelihoods of fishing communities, according to a report published by the Bangladeshi daily Prothom Alo. Unlike visible pollutants such as plastic waste or industrial sludge, pharmaceutical residues leave no obvious trace — yet they remain biologically active long after entering waterways.
The Science Behind the Silent Threat
Environmental scientist Prof. Dr Shahriar Hossain, cited in the Prothom Alo report, warned that pharmaceutical compounds can interact with aquatic organisms and microorganisms well after being discharged into water bodies. Previous research has already detected such compounds in Bangladeshi rivers, including the Old Brahmaputra. A 2026 study examining water sources in Gazipur found pharmaceutical compounds and heavy metals in hospital wastewater, pharmaceutical-industry effluents, municipal wastewater, and river water — underscoring how widespread the contamination has become.
Two Major Sources of Contamination
The report identifies pharmaceutical manufacturing as the first and primary source of pollution. Wastewater generated during drug production contains APIs, solvents, chemical intermediates, metals, and other contaminants. Dr Hossain noted that where effluent-treatment systems are 'absent, inadequate or poorly operated, these substances can enter surrounding waterways.' He further cautioned that any treatment system incapable of removing biologically active pharmaceutical compounds is 'not an adequate solution.'
The second major source identified is unused and expired medicines discarded in households. Once pharmaceutical products enter sewage systems, they can reach rivers and other water bodies — particularly where wastewater treatment infrastructure is inadequate. Hospitals and clinics compound the problem: large volumes of antibiotics, painkillers, hormones, and cancer medicines inevitably expire or go unused. Without proper segregation, collection, and treatment, this waste can infiltrate general healthcare waste streams and eventually surface waters.
Antimicrobial Resistance: The Most Dangerous Dimension
The report describes antimicrobial resistance (AMR) as 'perhaps the most dangerous dimension of pharmaceutical pollution.' Dr Hossain explained that antibiotic residues in the environment 'can create conditions that favour the survival and proliferation of resistant organisms' — a dynamic that could accelerate the global AMR crisis. This concern is not new: health researchers and international bodies have for years flagged South Asian river systems as AMR hotspots, with Bangladesh's dense pharmaceutical manufacturing base making it a particular area of concern.
Impact on Marine Life and Fishing Communities
Beyond AMR, pharmaceutical compounds can disrupt the endocrine systems of fish and other aquatic organisms. Dr Hossain noted that hormonal substances 'can potentially influence reproduction, development and behaviour,' while other residues can alter ecological relationships among microorganisms. This is significant for a country where fish consumption is a dietary staple. The report warns that fishing communities are 'particularly vulnerable,' as environmental degradation could simultaneously threaten their health and their primary source of income.
Calls for Corporate and Regulatory Action
The author of the report urged Bangladesh's pharmaceutical sector to invest in cleaner production, advanced wastewater treatment, pollution prevention, safer chemical management, and transparent environmental reporting. Dr Hossain emphasised that 'corporate responsibility cannot stop at producing a quality medicine — it must extend to the entire life cycle of that medicine.' Analysts note that Bangladesh's pharmaceutical industry, while rapidly growing and increasingly export-oriented, has faced longstanding criticism over environmental compliance gaps in manufacturing clusters.
Point of View
Yet enforcement remains inconsistent. Bangladesh's pharma sector has grown rapidly into a significant export industry, creating political and commercial incentives to look away from effluent compliance. The AMR angle is the most consequential — resistant organisms bred in polluted rivers do not respect borders, making this a regional public-health issue, not just a Bangladeshi one. The call for full life-cycle corporate responsibility is correct in principle, but without mandatory third-party environmental audits and credible penalties, it risks remaining aspirational.
NationPress
4 Oct 2026
Frequently Asked Questions
What is pharmaceutical pollution in Bangladesh's rivers?
It refers to the contamination of Bangladeshi waterways by active pharmaceutical ingredients (APIs) — including antibiotics, hormones, and anti-inflammatory drugs — discharged through manufacturing wastewater, hospital effluents, and improperly disposed household medicines. Unlike visible pollutants, these residues are colourless and odourless but remain biologically active in the environment.
Why is antimicrobial resistance the most dangerous risk?
Antibiotic residues in rivers can create conditions that allow resistant bacteria to survive and multiply, accelerating the global antimicrobial resistance (AMR) crisis. According to environmental scientist Prof. Dr Shahriar Hossain, this is 'perhaps the most dangerous dimension of pharmaceutical pollution' because resistant organisms, once established in water systems, are extremely difficult to eliminate.
Which communities are most affected by this pollution?
Fishing communities in Bangladesh are identified as particularly vulnerable, as they depend directly on the rivers both for food and income. Widespread fish consumption across the country means the health risks of pharmaceutical-contaminated waterways extend to the broader population as well.
What are the main sources of pharmaceutical pollution in Bangladesh?
The two primary sources identified in the Prothom Alo report are pharmaceutical manufacturing — where wastewater containing APIs, solvents, and heavy metals enters waterways when effluent treatment is absent or inadequate — and unused or expired medicines discarded by households, hospitals, and clinics that eventually reach sewage and river systems.
What solutions have been proposed to address the problem?
Prof. Dr Hossain and the report's author urge Bangladesh's pharmaceutical sector to invest in cleaner production processes, advanced wastewater treatment capable of removing biologically active compounds, safer chemical management, and transparent environmental reporting. They argue that corporate responsibility must extend to the entire life cycle of a medicine, not just its manufacture.
